Objective:The effect of Tranexamic Acid on prevention of increased hemorrhage in Traumatic Brain Injury Design: This randomized double-blind clinical trial will be done on 150 patients with traumatic brain injury. Setting and Conduct: In this study, patients who referred to the hospital within 8 hours of injury; after doing a CT scan of the brain and the existence of a cerebral hemorrhage, will randomly divided into two experimental and control groups. Participants including major eligibility criteria: Inclusion criteria: Any traumatic brain lesion in CT scan such as sub arachnid hemorrhage, intra Cranial hemorrhage, subdural hemorrhage …; age 15 years and more; non penetrating trauma; the first CT scan within 8 hours after trauma; no need to brain surgery during 8 hours. Exclusion criteria: patients with coagolopathy; serum creatinine more than 2 mg; massive organs injury; hospital admission after 8 hours from trauma; pregnant patients; drugs which induced coaglopathy; patients who are unable to perform secondary CT scan. Intervention: In the experimental group, the initial dose of 1 gr Tranexamic Acid in 100 ml of serum will be infused over 10 minutes and then the maintenance dose of 1 gr in 1000 ml of saline will be infused over 8 hours . In the control group, sodium chloride 0.09% will be used in a similar method. 24 h after drugs administration, patients will evaluate by CT scan. Main outcome measures: Patients will evaluate regarding hemorrhagic mass size, new hemorrhage in CT scan, mass effects on brain tissue, and brain ischemic lesion. Then patient outcome regarding response to treatment, Hemorrhagic mass size increase of at least 25% of its original size, need to brain surgery and patient death or recovery will be assessed. Also the adverse effect of Tranexamic Acid including nausea and vomiting, abdominal pain, diarrhea and vein thrombosis will be recorded. Three months after drug administration, outcome measure will be recorded based on the Glasgow Outcome Scale